Comparative Pharmacology
Head-to-head clinical analysis: UZEDY versus VERSACLOZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UZEDY versus VERSACLOZ.
UZEDY vs VERSACLOZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atypical antipsychotic; antagonist at dopamine D2 and serotonin 5-HT1A/5-HT2A receptors; partial agonist at serotonin 5-HT1A receptors
Clozapine is an atypical antipsychotic that binds to dopamine D4 and serotonin 5-HT2A receptors with high affinity, and also to D1, D2, D3, D5, 5-HT1A, 5-HT1C, 5-HT3, 5-HT6, 5-HT7, alpha-adrenergic, histamine H1, and muscarinic M1-M5 receptors.
UZEDY (risperidone) extended-release injectable suspension: 75 mg, 100 mg, 150 mg, or 200 mg IM gluteal injection every 2 weeks after a single oral dose of 2 mg risperidone for 2 days; or 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, or 150 mg IM every 4 weeks after oral overlap for 2 days. Oral risperidone may be omitted if patient is stable on oral risperidone 2 mg/day.
Initial: 12.5 mg orally once or twice daily; titrate by 25-50 mg/day to target dose of 300-450 mg/day divided, with maximum 900 mg/day.
None Documented
None Documented
Terminal half-life approximately 30 days (range 23–37 days) after subcutaneous injection, supporting monthly dosing.
Terminal elimination half-life ~12 hours (range 6-33 hours); steady-state achieved within 7-10 days; requires gradual dose titration to mitigate seizure risk.
Primarily renal: 80% as metabolites, 1% unchanged. Biliary/fecal: 20%.
Renal: ~50% (30% as unchanged drug, rest as metabolites); fecal: ~30% (via bile); minor biliary elimination.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic